Esperion is a pharmaceutical company focused on developing and commercializing first-in-class, oral therapies for low-density, lipoprotein cholesterol (LDL-C) lowering for the treatment of patients with elevated LDL-C. Bempedoic acid (ETC-1002), the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol biosynthesis, decreases intracellular cholesterol, up-regulates LDL-recptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C.

Contact us for more information about partnering with Esperion.